Building handprints of complex diseases: the U-BIOPRED case

B. De Meulder (Lyon, France)

Source: ERS Lung Science Conference 2016
Number: 9

PDF journal article, handout or slidesSlide presentationWebcastMultimedia files

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
B. De Meulder (Lyon, France). Building handprints of complex diseases: the U-BIOPRED case. ERS Lung Science Conference 2016

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Developing integrated handprints of severe asthma: the U-BIOPRED approach
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014

Childhood tuberculosis outbreaks in EU/EEA: A systematic review
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations
Year: 2013

The European union standards for tuberculosis care: Do they need an update?
Source: International Congress 2014 – Tuberculosis: public health and primary prevention
Year: 2014

Presenting the European Forum for TB Innovation: innovative thinking in progressing towards TB elimination in Europe},
Source: Eur Respir J 2012; 40: 806-808
Year: 2012

Tuberculosis elimination: a dream or a reality? The case of Oman
Source: Eur Respir J, 51 (1) 1702027; 10.1183/13993003.02027-2017
Year: 2018

Improving tuberculosis case finding through active contact tracing: A community based cross-sectional survey in central Ethiopia
Source: International Congress 2016 – Microbiology: bronchoalveolar lavage (BAL) and PCR
Year: 2016

Tuberculosis elimination: dream or reality? The case of Cyprus
Source: Eur Respir J 2014; 44: 543-546
Year: 2014

Latent TB in healthcare workers from high prevalence countries at city hospital Sunderland foundation trust (CHSFT); epidemiology and management
Source: International Congress 2016 – Active and latent tuberculosis: biomarkers
Year: 2016

Oral Presentations by Marie Curie Fellows of their fellowship's experience, professional achievements & career impact: "The immunopathology of allergic asthma in the developing neonatal immune system" (from Utrecht NETHERLANDS to Ghent BELGIUM, 01.09.2009 - 01.09.2010) - special focus on the challenge of staying onsite at the Host Unit in BELGIUM
Source: Annual Congress 2012 - Fellows' Get-Together
Year: 2012

Active case finding of tuberculosis, Tomsk (Russia)
Source: International Congress 2015 – WHO guidelines in TB and clinical practice
Year: 2015

Asthma: a complex syndrome of many diseases?
Source: International Congress 2014 – ME09 Asthma: a complex syndrome of many diseases?
Year: 2014

Implementation of personalized treatment of asthma by improved phenotyping: Critical review of knowledge gaps and unmet research needs by the European asthma research & innovation partnership (EARIP) expert panel
Source: International Congress 2016 – Phenotyping asthma
Year: 2016

Ownership of written asthma action plans in a large Australian survey
Source: Annual Congress 2013 –Management of respiratory diseases in primary care
Year: 2013

The disease burden of mild asthma: Findings from a 2013 real world survey
Source: International Congress 2016 – Asthma and allergy in infancy: from risk factors to mortality
Year: 2016

The virtual asthma clinic: Description and analysis of website-use
Source: International Congress 2016 – Techniques and tools in paediatric asthma
Year: 2016

Notified or missed cases? An assessment of successful linkage for referred tuberculosis patients in South India
Source: International Congress 2015 – Case series and clinical conundrums in TB
Year: 2015

Late-breaking abstract: Asthma through childhood; do children remit from their disease?
Source: Annual Congress 2011 - Risk and detection of childhood asthma and allergy
Year: 2011

Digital health technology for the end TB strategy: Developing priority products and making them work
Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics
Year: 2016